RESUMO
Invasive fungal disease (IFD) is a major infectious complication in patients with hematological malignancies. In this study, we examined 4889 courses of chemotherapy in patients with hematological diseases to establish a training dataset (n = 3500) by simple random sampling to develop a weighted risk score for proven or probable IFD through multivariate regression, which included the following variables: male patients, induction chemotherapy for newly diagnosed or relapsed disease, neutropenia, neutropenia longer than 10 days, hypoalbuminemia, central-venous catheter, and history of IFD. The patients were classified into three groups, which had low (0-10, ~1.2%), intermediate (11-15, 6.4%), and high risk ( > 15, 17.5%) of IFD. In the validation set (n = 1389), the IFD incidences of the groups were ~1.4%, 5.0%, and 21.4%. In addition, we demonstrated that antifungal prophylaxis offered no benefits in low-risk patients, whereas benefits were documented in intermediate (2.1% vs. 6.6%, P = 0.007) and high-risk patients (8.4% vs. 23.3%, P = 0.007). To make the risk score applicable for clinical settings, a pre-chemo risk score that deleted all unpredictable factors before chemotherapy was established, and it confirmed that anti-fungal prophylaxis was beneficial in patients with intermediate and high risk of IFD. In conclusion, an objective, weighted risk score for IFD was developed, and it may be useful in guiding antifungal prophylaxis.
Assuntos
Antifúngicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias Hematológicas/tratamento farmacológico , Infecções Fúngicas Invasivas/tratamento farmacológico , Infecções Fúngicas Invasivas/epidemiologia , Adulto , China/epidemiologia , Feminino , Neoplasias Hematológicas/patologia , Humanos , Incidência , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Neutropenia/microbiologia , Profilaxia Pré-Exposição , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Índice de Gravidade de Doença , Adulto JovemRESUMO
Febrile neutropenia (FN) is the main reason for antibiotic prescription in hematology wards where, on the other hand, antibiotic stewardship (AS) is poorly explored. The objectives of the present study were to evaluate (1) the impact of an AS intervention on antibiotic consumption and (2) the applicability and acceptance rate of the intervention and its clinical impact. A persuasive AS intervention based on European Conference on Infection in Leukaemia (ECIL) guidelines for FN was implemented in a high-risk hematology ward in a tertiary referral public university hospital. This included the creation and diffusion of flow charts on de-escalation and discontinuation of antibiotics for FN, and the introduction in the team of a doctor dedicated to the implementation of flow charts and to antibiotic prescription revision. All consecutive patients receiving antibiotics during hospitalization were included. A segmented linear regression model was performed for the evaluation of antibiotic consumption, taking into account 1-year pre-intervention period and 6-month intervention period. Overall, 137 consecutive antibiotic prescriptions were re-evaluated, 100 prescriptions were for FN. A significant reduction of the level of carbapenem consumption was observed during the intervention period (level change (estimate coefficient ± standard error) = - 135.28 ± 59.49; p = 0.04). Applicability and acceptability of flow charts were high. No differences in terms of intensive care unit transfers, bacteremia incidence, and mortality were found. A persuasive AS intervention in hematology significantly reduced carbapenem consumption without affecting outcome and was well accepted. This should encourage further applications of ECIL guidelines for FN.
Assuntos
Antibacterianos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Uso de Medicamentos/estatística & dados numéricos , Neutropenia/tratamento farmacológico , Adulto , Idoso , Antibacterianos/economia , Infecções Bacterianas/microbiologia , Feminino , Febre/tratamento farmacológico , Febre/microbiologia , França , Hematologia , Hospitalização , Humanos , Unidades de Terapia Intensiva/estatística & dados numéricos , Análise de Séries Temporais Interrompida , Masculino , Pessoa de Meia-Idade , Neutropenia/microbiologia , Resultado do Tratamento , Suspensão de Tratamento/estatística & dados numéricosRESUMO
Antimicrobial resistance among uropathogens has increased the rates of infection-related morbidity and mortality. Antofloxacin is a novel fluoroquinolone with broad-spectrum antibacterial activity against urinary Gram-negative bacilli, such as Escherichia coli This study monitored the in vivo efficacy of antofloxacin using bioluminescent imaging and determined pharmacokinetic (PK)/pharmacodynamic (PD) targets against E. coli isolates in a neutropenic murine thigh infection model. The PK properties were determined after subcutaneous administration of antofloxacin at 2.5, 10, 40, and 160 mg/kg of body weight. Following thigh infection, the mice were treated with 2-fold-increasing doses of antofloxacin from 2.5 to 80 mg/kg administered every 12 h. Efficacy was assessed by quantitative determination of the bacterial burdens in thigh homogenates and was compared with the bioluminescent density. Antofloxacin demonstrated both static and killing endpoints in relation to the initial burden against all study strains. The PK/PD index area under the concentration-time curve (AUC)/MIC correlated well with efficacy (R2 = 0.92), and the dose-response relationship was relatively steep, as observed with escalating doses of antofloxacin. The mean free drug AUC/MIC targets necessary to produce net bacterial stasis and 1-log10 and 2-log10 kill for each isolate were 38.7, 66.1, and 147.0 h, respectively. In vivo bioluminescent imaging showed a rapid decrease in the bioluminescent density at free drug AUC/MIC exposures that exceeded the stasis targets. The integration of these PD targets combined with the results of PK studies with humans will be useful in setting optimal dosing regimens for the treatment of urinary tract infections due to E. coli.
Assuntos
Antibacterianos/farmacologia , Infecções por Escherichia coli/tratamento farmacológico , Escherichia coli/efeitos dos fármacos , Neutropenia/microbiologia , Ofloxacino/análogos & derivados , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos/métodos , Escherichia coli/genética , Escherichia coli/isolamento & purificação , Feminino , Meia-Vida , Camundongos Endogâmicos ICR , Testes de Sensibilidade Microbiana , Ofloxacino/administração & dosagem , Ofloxacino/farmacocinética , Ofloxacino/farmacologia , Plasmídeos/genética , Infecções dos Tecidos Moles/tratamento farmacológico , Infecções dos Tecidos Moles/microbiologia , Coxa da Perna/microbiologiaRESUMO
OBJECTIVES: Mucormycosis is an invasive fungal infection afflicting immunocompromised patients, causing a significant degree of morbidity and mortality. The purpose of the study was to provide a comprehensive analysis describing the epidemiology and outcome of mucormycosis in the scenario of HIV infection. METHODS: We systematically searched PubMed for reports about mucormycosis associated with HIV. Eligible studies describe the predisposing factor, clinical form, treatment, and survival outcome. RESULTS: We included 61 articles from 212 reviewed abstracts, corresponding to 67 cases. Patients were mostly men (68.2%) with a median CD4(+) count of 47 [IQR 17-100] cells/mm(3). Intravenous drug use (50%), neutropenia (29.7%) and corticosteroid use (25%) were the predominant associated factors. The main clinical forms were disseminated (20.9%), renal (19.4%), and rhino-cerebral (17.9%). Rhizopus (45.5%) and Lichtheimia spp (30.3%) were the main fungal isolates. Treatment consisted of antifungal therapy and surgery in 38.8%. Overall mortality rate was 52.2%, and varied with the site of infection: 92.9% for disseminated disease, 62.5% for cerebral disease, 60% for pulmonary infection, and 36.4% for cutaneous infection. Survival was worse for those who did not initiate antifungals (p = .04), who were antiretroviral naïve (p = .01), who were admitted to ICU (p = .003) or had disseminated disease (p = .007). CONCLUSIONS: Mucormycosis is a life-threatening infection in HIV patients and clinician should be aware of this co-infection in the differential diagnosis of HIV opportunistic infections.
Assuntos
Coinfecção , Efeitos Psicossociais da Doença , Infecções por HIV/complicações , Mucormicose/complicações , Mucormicose/epidemiologia , Adulto , Antifúngicos/uso terapêutico , Coinfecção/tratamento farmacológico , Coinfecção/microbiologia , Coinfecção/mortalidade , Coinfecção/virologia , Feminino , Infecções por HIV/virologia , Humanos , Hospedeiro Imunocomprometido/imunologia , Pneumopatias/complicações , Pneumopatias/microbiologia , Masculino , Pessoa de Meia-Idade , Mucormicose/tratamento farmacológico , Mucormicose/mortalidade , Neutropenia/complicações , Neutropenia/microbiologia , Neutropenia/virologia , Rhizopus/isolamento & purificação , Fatores de RiscoRESUMO
BACKGROUND: Anticancer therapy entails qualitative and quantitative changes in the physiological bacterial flora of the organism, including the oral microflora. OBJECTIVES: The aim of the study was to assess the number of cariogenic bacteria - Streptococcus mutans and Lactobacillus spp. - in the saliva of children with chemotherapy-induced neutropenia, and the relationship between the dynamics of neutrophils in the blood and the number of cariogenic bacteria in the saliva. MATERIAL AND METHODS: The study included 52 children aged 3-17.5 years, diagnosed with cancer and undergoing antineoplastic treatment. The control group comprised 52 generally healthy children matched for age and gender. Both groups underwent microbiological analysis of the saliva. The Dentocult SM Strip Mutans test (Orion Diagnostica, Espoo, Finland) was used to evaluate the number of Streptococcus mutans colonies in the saliva, while the Dentocult LB test (Orion Diagnostica) was used to assess the number of Lactobacillus spp. bacteria. The statistical analysis was carried out using STATISTICA 10 software (StatSoft Inc., Tulsa, USA). RESULTS: The statistical analysis using Kendall's tau test showed a significant inverse correlation between the number of neutrophils in the blood and the number of the Streptococcus mutans and Lactobacillus spp. colonies in the saliva of the children undergoing anticancer therapy. The highest titres of cariogenic bacteria in the saliva were observed during severe neutropenia, which was frequently observed between day 7 and day 21 of the chemotherapy course. CONCLUSIONS: A significant increase in the number of cariogenic bacteria in the saliva during episodes of chemotherapy-induced neutropenia suggests that the activity of dental caries increases in children undergoing antineoplastic treatment.
Assuntos
Antineoplásicos/efeitos adversos , Cárie Dentária/microbiologia , Lactobacillus/isolamento & purificação , Neutropenia/microbiologia , Saliva/microbiologia , Streptococcus mutans/isolamento & purificação , Adolescente , Fatores Etários , Antineoplásicos/administração & dosagem , Estudos de Casos e Controles , Criança , Pré-Escolar , Contagem de Colônia Microbiana , Esquema de Medicação , Feminino , Humanos , Masculino , Neutropenia/induzido quimicamente , Índice de Gravidade de Doença , Fatores de TempoRESUMO
The China Assessment of Antifungal Therapy in Hematological Disease study, the first large-scale observational study of invasive fungal disease (IFD) in China, enrolled 1401 patients undergoing hematopoietic stem cell transplantation (HSCT) (75.2% allogeneic and 24.8% autologous) at 31 hospitals across China. The overall incidence of proven or probable IFD was 7.7% (108 of 1401); another 266 cases (19.0%) were possible IFD. After allogeneic or autologous HSCT, the incidence of proven/probable IFD was 8.9% (94 of 1053) and 4.0% (14 of 348), respectively. Some cases (14 of 108) developed during conditioning before transplantation. The cumulative incidence of proven/probable IFD increased steeply in the first month after transplantation and after 6 months, the incidence was significantly higher in allogeneic than it was in autologous transplant recipients (9.2% versus 3.5%; P = .001) and when stem cells were derived from cord blood or bone marrow and peripheral blood (P = .02 versus other sources). Independent risk factors for proven/probable IFD in allogeneic HSCT were diabetes, HLA-matched unrelated donor, prolonged severe neutropenia (absolute neutrophil count > 500/mm(3) for >14 days), and immunosuppressants (odds ratio, 2.0 to 3.4 for all). Antifungal prophylaxis was independently protective (P = .01). Previous IFD and prolonged severe neutropenia were significant independent risk factors among autologous transplantation patients (P < .01, P = .04, respectively). In total, 1175 (83.9%) patients received antifungal prophylaxis (91.6% triazoles) and 514 (36.7%) were treated in the hospital with therapeutic antifungals (89.1% triazoles; median 27 days). Empirical, pre-emptive, and targeted antifungals were used in 82.3%, 13.6%, and 4.1% of cases, respectively. Overall mortality (13.4%; 188 deaths) was markedly higher in patients with proven (5 of 16; 31.3%), probable (20 of 92; 21.7%), or possible (61 of 266; 22.9%) IFD; allogeneic (171 of 1053; 16.2%) rather than autologous (17 of 348; 4.9%) HSCT and was significantly higher in patients receiving pre-emptive (18.6%) rather than empirical (6.1%) or targeted (9.5%) antifungal therapy (P = .002). Improvements in the selection and timing of prophylactic antifungals would be welcome. Health care providers should remain alert to the increased risk of IFD and associated mortality in allogeneic HSCT recipients and the ongoing risk of IFD even after discharge from the hospital.
Assuntos
Antifúngicos/uso terapêutico , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Micoses/tratamento farmacológico , Condicionamento Pré-Transplante , Triazóis/uso terapêutico , Adolescente , Adulto , China , Doença Crônica , Feminino , Doença Enxerto-Hospedeiro/imunologia , Doença Enxerto-Hospedeiro/mortalidade , Doença Enxerto-Hospedeiro/patologia , Doença Enxerto-Hospedeiro/prevenção & controle , Neoplasias Hematológicas/imunologia , Neoplasias Hematológicas/mortalidade , Neoplasias Hematológicas/patologia , Humanos , Imunossupressores/uso terapêutico , Incidência , Masculino , Micoses/etiologia , Micoses/microbiologia , Micoses/mortalidade , Agonistas Mieloablativos/uso terapêutico , Neutropenia/tratamento farmacológico , Neutropenia/etiologia , Neutropenia/microbiologia , Neutropenia/mortalidade , Prognóstico , Estudos Prospectivos , Fatores de Risco , Irmãos , Análise de Sobrevida , Transplante Autólogo , Transplante Homólogo , Resultado do Tratamento , Doadores não RelacionadosRESUMO
BACKGROUND: In patients undergoing induction chemotherapy for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), posaconazole has been proven more effective in the prevention of invasive fungal infection (IFI) than fluconazole or itraconazole (standard azoles) The current analysis seeks to estimate the cost effectiveness of prophylactic posaconazole compared with standard azoles in AML or MDS patients with severe chemotherapy-induced neutropenia in Sweden. METHODS: A decision-analytic model was used to estimate life expectancy, costs, and quality-adjusted life-years (QALYs). Efficacy data were derived from a phase III clinical trial. Life expectancy and quality of life data were collected from the literature. A modified Delphi method was used to gather expert opinion on resource use for an IFI. Unit costs were captured from hospital and pharmacy pricelists. A probabilistic sensitivity analysis (PSA) was used to investigate the impact of uncertainty in the model parameters on the cost-effectiveness results. RESULTS: The estimated mean direct cost per patient with posaconazole prophylaxis was 46,893 Swedish kronor (SEK) (5,387) and SEK50,017 (5,746) with standard azoles. Prophylaxis with posaconazole resulted in 0.075 QALYs gained compared with standard azoles. At a cost-effectiveness threshold of SEK500,000/QALY the PSA demonstrated a more than 95 % probability that posaconazole is cost effective versus standard azoles for the prevention of IFI in high-risk neutropenic patients in Sweden. CONCLUSION: Given the assumptions, methods, and data used, posaconazole is expected to be cost effective compared with standard azoles when used as antifungal prophylaxis in AML or MDS patients with chemotherapy-induced prolonged neutropenia in Sweden.
Assuntos
Antifúngicos/economia , Antifúngicos/uso terapêutico , Fluconazol/uso terapêutico , Itraconazol/uso terapêutico , Micoses/complicações , Micoses/prevenção & controle , Neutropenia/complicações , Triazóis/uso terapêutico , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Ensaios Clínicos Fase III como Assunto , Análise Custo-Benefício , Feminino , Fluconazol/administração & dosagem , Fluconazol/economia , Humanos , Itraconazol/administração & dosagem , Itraconazol/economia , Leucemia Mieloide Aguda/complicações , Leucemia Mieloide Aguda/tratamento farmacológico , Leucemia Mieloide Aguda/microbiologia , Expectativa de Vida , Masculino , Pessoa de Meia-Idade , Micoses/tratamento farmacológico , Micoses/microbiologia , Síndromes Mielodisplásicas/complicações , Síndromes Mielodisplásicas/tratamento farmacológico , Síndromes Mielodisplásicas/microbiologia , Neutropenia/induzido quimicamente , Neutropenia/microbiologia , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Suécia , Triazóis/administração & dosagem , Triazóis/economiaRESUMO
Animal models of infection have been used to demonstrate the therapeutic failure of "bioequivalent" generic products, but their applicability for this purpose requires the accurate identification of those products that are truly bioequivalent. Here, we present data comparing one intravenous generic product of metronidazole with the innovator product in a neutropenic mouse thigh anaerobic infection model. Simultaneous experiments allowed comparisons (generic versus innovator) of potency and the concentration of the active pharmaceutical ingredient (API), analytical chemistry (liquid chromatography/mass spectrometry [LC/MS]), in vitro susceptibility testing, single-dose serum pharmacokinetics (PK) in infected mice, and in vivo pharmacodynamics (PD) against Bacteroides fragilis ATCC 25825 in synergy with Escherichia coli SIG-1 in the neutropenic mouse thigh anaerobic infection model. The Hill dose-response model followed by curve-fitting analysis was used to calculate and compare primary and secondary PD parameters. The generic and the innovator products were identical in terms of the concentration and potency of the API, chromatographic and spectrographic profiles, MIC and minimal bactericidal concentrations (MBC) (2.0 mg/liter), and mouse PK. We found no differences between products in bacteriostatic doses (BD) (15 to 22 mg/kg of body weight per day) or the doses needed to kill 1 log (1LKD) (21 to 29 mg/kg per day) or 2 logs (2LKD) (28 to 54 mg/kg per day) of B. fragilis under dosing schedules of every 12 h (q12h), q8h, or q6h. The area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC ratio) was the best PD index to predict the antibacterial efficacy of metronidazole (adjusted coefficient of determination [AdjR(2)] = 84.6%), and its magnitude to reach bacteriostasis in vivo (56.6 ± 5.17 h) or to kill the first (90.8 ± 9.78 h) and second (155.5 ± 22.2 h) logs was the same for both products. Animal models of infection allow a thorough demonstration of the therapeutic equivalence of generic antimicrobials.
Assuntos
Antibacterianos/farmacocinética , Bacteroides fragilis/efeitos dos fármacos , Medicamentos Genéricos/farmacocinética , Metronidazol/farmacocinética , Staphylococcus aureus/efeitos dos fármacos , Animais , Antibacterianos/farmacologia , Área Sob a Curva , Infecções por Bacteroides/tratamento farmacológico , Infecções por Bacteroides/microbiologia , Bacteroides fragilis/fisiologia , Cromatografia Líquida , Medicamentos Genéricos/farmacologia , Feminino , Injeções Intravenosas , Espectrometria de Massas , Metronidazol/farmacologia , Camundongos , Testes de Sensibilidade Microbiana , Neutropenia/complicações , Neutropenia/tratamento farmacológico , Neutropenia/microbiologia , Infecções Estafilocócicas/complicações , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/fisiologia , Equivalência Terapêutica , Coxa da Perna/microbiologiaRESUMO
The objectives of this study were to develop a population pharmacokinetic (PK) model of meropenem, to simulate the percent time above minimum inhibitory concentration (%T > MIC) at various MICs, and to estimate effective dosage regimens by calculating the target attainment rates against various strains of bacteria. A total of 209 plasma samples (1-3 concentrations per patient) were obtained from 98 adult Japanese patients with febrile neutropenia in an open-labeled Phase 3 study. The final population PK model was fit to a two-compartment model with zero-order input. Creatinine clearance had a positive significant correlation with CL. Gender had a significant effect on Vc; however, this effect was small, and the PK profile in male patients was similar to that in female patients. The population PK parameters developed in this study are useful in simulating PK profiles of meropenem at various dosage regimens precisely for calculation of %T > MIC. The PK-PD analysis indicated that 0.5 g every 6 h (q6h) was more effective than 1 g q12h, although provided 2 g per day in total. A meropenem dosage regimen of 1 g q8h and/or longer infusion duration was better against a pathogen of comparatively low sensitivity, Pseudomonas aeruginosa (for MIC ≥2 µg/ml). Although causative bacteria were identified in a small number of patients, the target attainment rates at 75%T > MIC (89%) were comparable to microbiological response (89%). The present PK-PD analyses under various conditions are useful in the treatment of febrile neutropenia.
Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Neutropenia/metabolismo , Tienamicinas/administração & dosagem , Tienamicinas/farmacocinética , Adolescente , Adulto , Idoso , Antibacterianos/farmacologia , Bactérias/efeitos dos fármacos , Simulação por Computador , Feminino , Febre/tratamento farmacológico , Febre/metabolismo , Febre/microbiologia , Humanos , Japão , Testes de Função Renal , Masculino , Meropeném , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Modelos Biológicos , Método de Monte Carlo , Neutropenia/tratamento farmacológico , Neutropenia/microbiologia , Tienamicinas/farmacologiaRESUMO
OBJECTIVES: We examined health care use in conjunction with primary prophylaxis use of colony stimulating factors (CSF) during patients' initial course of chemotherapy. METHODS: This retrospective cohort study identified adults aged 25 years and older with a diagnosis of breast, colorectal, or nonsmall cell lung cancer between 2002 and 2005 from the Western Washington Surveillance Epidemiology and End Results Puget Sound registry. We linked these records to health insurance claims from four payers representing 75% of those insured in the state. Claims records were used to determine chemotherapy regimen type, CSF use, febrile neutropenia occurrences, and supportive care. Chemotherapy regimens were categorized as conferring high, intermediate, or low risk of myelosuppression according to the National Comprehensive Cancer Network guidelines. CSF use was described as primary prophylaxis, other, or none. Antibiotics and antifungal and antiviral agents per National Comprehensive Cancer Network guidelines for supportive care for cancer infection were categorized using Healthcare Common Procedure Coding System and National Drug Code assignments. RESULTS: Use of CSF as primary prophylaxis is not significantly associated with a reduction in antibiotic use or inpatient or outpatient visits. Primary prophylactic CSF use was associated with less use of antiviral drugs. CONCLUSIONS: CSF use is not associated with a reduction in health care use, with the exception of antiviral drug use. Given the expense associated with CSF use, pragmatic trials and additional research are needed to further assess the affects of CSF on health care use.
Assuntos
Antineoplásicos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Fatores Estimuladores de Colônias/uso terapêutico , Neoplasias/tratamento farmacológico , Neutropenia/prevenção & controle , Idoso , Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Feminino , Humanos , Revisão da Utilização de Seguros , Masculino , Pessoa de Meia-Idade , Neoplasias/sangue , Neutropenia/induzido quimicamente , Neutropenia/microbiologia , Estudos Retrospectivos , Programa de SEER , WashingtonRESUMO
CONTEXT: Use of once daily aminoglycosides continues to increase for the pediatric population, including oncology patients. Concerns have been identified and still need to be resolved including the optimal dose, frequency, and monitoring parameters. OBJECTIVE: We completed a study to determine if empiric use of gentamicin 7 mg/kg once daily in pediatric patients admitted with febrile neutropenia provided extrapolated peaks and drug-free intervals consistent with suggested preferred levels. DESIGN: A review of the patient's chart was completed following their discharge from the hospital between September 2006 and October 2007. SETTING: A community hospital. PATIENTS: A consecutive sample of 17 encounters for pediatric patients admitted for febrile neutropenia that received once daily gentamicin. MAIN OUTCOME MEASURES: Extrapolated peak levels and drug-free intervals. RESULTS: There were seven patients with a total of 17 encounters. The mean extrapolated peak level was 16.9 mg/L. The mean drug-free interval was 15.7 h. Both target peak and drug-free interval were obtained for two encounters (12%), which was one patient. CONCLUSION: Gentamicin 7 mg/kg/dose once daily does not provide preferred levels for all pediatric febrile neutropenic patients. Further investigation is required to ensure that once daily gentamicin regimens for pediatric oncology patients provide adequate clinical success.
Assuntos
Anti-Infecciosos/farmacocinética , Anti-Infecciosos/uso terapêutico , Gentamicinas/farmacocinética , Gentamicinas/uso terapêutico , Neutropenia/tratamento farmacológico , Adolescente , Anti-Infecciosos/administração & dosagem , Candidíase/tratamento farmacológico , Candidíase/microbiologia , Criança , Pré-Escolar , Creatinina/sangue , Feminino , Febre/etiologia , Gentamicinas/administração & dosagem , Meia-Vida , Humanos , Injeções Intravenosas , Infecções por Klebsiella/tratamento farmacológico , Infecções por Klebsiella/microbiologia , Leucemia Linfoide/complicações , Masculino , Neutropenia/complicações , Neutropenia/microbiologia , Projetos PilotoRESUMO
BACKGROUND: In August 2002, the antifungal prophylaxis algorithm for neutropenic hematology/oncology (NHO) patients at the Medical Center was changed from conventional amphotericin (AMB) to an azole (AZ) based regimen (fluconazole [FLU] in low-risk and voriconazole [VOR] in high-risk patients). The aim of our study was to compare outcomes associated with the two regimens, including breakthrough fungal infection, adverse drug events, and costs. METHODS: Adult, non-febrile, NHO patients who received prophylactic AMB from 01 August 2001-30 July 2002 or AZ from 01 August 2002-30 July 2003 were retrospectively evaluated. RESULTS: A total of 370 patients (AMB: n = 181; AZ: n = 216) associated with 580 hospitalizations (AMB: n = 259; AZ: n = 321) were included. The incidence of probable/definite breakthrough Aspergillus infections was similar among regimens (AMB: 1.9% vs AZ: 0.6%; p=0.19). A greater incidence of mild/moderate (24.7% vs. 5.3%; p < 0.0001) and severe renal dysfunction (13.5% vs. 4.4%; p < 0.0012) was observed with AMB. In contrast, patients treated with VOR were found to have an increased rate of severe hepatic toxicity (32.5%) compared with patients treated with either AMB (22.6%) or FLU (21.4%) (p = 0.05). While the AZ period was associated with a >$9,000 increase in mean total costs/hospitalization, the mean acquisition cost associated with AZ was only $947/hospitalization more than AMB. CONCLUSION: While an AZ-based regimen is associated with increased cost, the reduced rate of nephrotoxicity and availability of oral dosage forms, suggests that azoles be used preferentially over AMB. However, an increased rate of severe hepatic toxicity may be associated with VOR.
Assuntos
Anfotericina B/uso terapêutico , Antibioticoprofilaxia , Antifúngicos/uso terapêutico , Fluconazol/uso terapêutico , Micoses/prevenção & controle , Neutropenia/microbiologia , Pirimidinas/uso terapêutico , Triazóis/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Anfotericina B/efeitos adversos , Anfotericina B/economia , Antibioticoprofilaxia/efeitos adversos , Antibioticoprofilaxia/economia , Antifúngicos/efeitos adversos , Antifúngicos/economia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Quimioterapia Combinada , Feminino , Fluconazol/efeitos adversos , Fluconazol/economia , Humanos , Masculino , Pessoa de Meia-Idade , Pirimidinas/efeitos adversos , Pirimidinas/economia , Estudos Retrospectivos , Triazóis/efeitos adversos , Triazóis/economia , VoriconazolRESUMO
Infection in immunocompromised hosts represents a serious clinical situation due the high morbidity and mortality it produces and is one of the most frequent complications in patients with cancer. In patients treated with chemotherapy the risk of infection mainly depends on the duration and intensity of neutropenia. It is essential to evaluate which pathogens are involved so that the most appropriate treatment can be selected a priori, as well as to determine the patient's general clinical status so that more or less aggressive treatment can be provided from the beginning, bearing in mind that "low risk" patients can be managed in the home. These questions can be determined by evaluating the patient's clinical history, physical examination, laboratory investigations, and radiological tests. Prompt initiation of broad-spectrum antibiotic therapy adapted to the the patient's risk is crucial.
Assuntos
Neutropenia , Infecções Oportunistas/prevenção & controle , Algoritmos , Febre , Humanos , Neoplasias/imunologia , Neutropenia/microbiologia , Neutropenia/terapia , Medição de RiscoRESUMO
The aim of this study was to evaluate the accuracy of E-test for the detection of synergy or antagonism of antibiotic combinations against Pseudomonas aeruginosa isolates from neutropenic patients. The activity of levofloxacin or grepafloxacin combined with ceftriaxone or cefotaxime against 20 P. aeruginosa clinical strains was assessed by checkerboard technique in comparison with results performed by E-test. The combination grepafloxacin + ceftriaxone appeared to be most effective (synergy, 55%) by checkerboard technique. The agreement between checkerboard and E-test results was 71.2%. Synergy was detected by checkerboard and E-test methods in 35 (43.8%) and 23 (31.3%) of 80 possible combinations, respectively. Antagonism was detected once (1.2%) by checkerboard method only. No major errors were recorded. E-test was preferable to checkerboard method for the total cost (reagent cost + cost of technologist time) (8,60 vs 21,80 euros/test, respectively). E-test appeared a promising alternative for testing antibiotic combinations although further testing should be performed to better refine this metodology.
Assuntos
Antibacterianos/farmacologia , Sinergismo Farmacológico , Quimioterapia Combinada/farmacologia , Testes de Sensibilidade Microbiana/métodos , Neutropenia/microbiologia , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/efeitos dos fármacos , Anemia/complicações , Anemia/microbiologia , Cefotaxima/farmacologia , Ceftriaxona/farmacologia , Análise Custo-Benefício , Fluoroquinolonas/farmacologia , Neoplasias Hematológicas/complicações , Neoplasias Hematológicas/microbiologia , Humanos , Levofloxacino , Testes de Sensibilidade Microbiana/economia , Ofloxacino/farmacologia , Piperazinas/farmacologia , Pseudomonas aeruginosa/crescimento & desenvolvimento , Pseudomonas aeruginosa/isolamento & purificaçãoRESUMO
The objective of this study was to evaluate the risk of acquiring gram-positive coccal infections in febrile neutropenic patients and to develop risk indexes for gram-positive and streptococcal infections. This prospective, multicenter study included 513 patients. The prevalence of gram-positive coccal infections was 21% (14% were staphylococcal infections and 7.8% were streptococcal infections). The mortality rate during the month after study enrollment was 5%. On multivariate analysis, the occurrence of gram-positive coccal infections was significantly associated with receipt of high-dose cytarabine therapy, proton pump inhibitors, and gut decontamination with colimycin without glycopeptides and presence of chills. Staphylococcal infection was significantly associated with use of nonabsorbable colimycin, and streptococcal infection was associated with diarrhea, use of nonabsorbable antifungals, receipt of high-dose cytarabine, and gut decontamination with colimycin. The relative risks for streptococcal infection were 2.9, 13.2, and 20.7 in the presence of 1, 2, and > or =3 parameters, respectively. Risk factors for staphylococcal and streptococcal infections differ among neutropenic patients. A simple scoring system for predicting streptococcal infection is proposed.
Assuntos
Antibacterianos/uso terapêutico , Infecções por Bactérias Gram-Positivas/epidemiologia , Neutropenia/complicações , Infecções Estreptocócicas/epidemiologia , Febre/etiologia , Bactérias Gram-Positivas/efeitos dos fármacos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Bactérias Gram-Positivas/etiologia , Infecções por Bactérias Gram-Positivas/mortalidade , Humanos , Neutropenia/microbiologia , Prevalência , Estudos Prospectivos , Fatores de Risco , Infecções Estreptocócicas/tratamento farmacológico , Infecções Estreptocócicas/etiologiaRESUMO
The objective of this study was to determine the susceptibility breakpoint of a new carbapenem, ertapenem (MK-0826), against Streptococcus pneumoniae strains based on bacterial density and survival studies in a murine thigh infection model. Sixteen S. pneumoniae isolates for which MICs ranged from 0.015 to 4.0 mg/liter were tested with neutropenic ICR mice. Animals were infected with bacteria at 10(5) to 10(6) CFU per thigh and were treated with ertapenem starting at 2 h postinfection for 4 days. Ertapenem was given subcutaneously at 50 mg/kg of body weight every 6 h, which simulates the human pharmacodynamic profile (in particular, the duration of time that the concentration of free drug remains above the MIC of 2 mg/liter). At 0 and 24 h postinfection, thighs were harvested for bacterial density determination. Survival was assessed during 4 days of therapy and 3 days after the therapy. A protein binding study was conducted with mice by use of the ultrafiltration method. Protein binding in mice was approximately 95%, which is comparable to that in humans. The average change in bacterial density ranged from -0.22 to -4.4 log CFU per thigh over 24 h compared to 0-h controls. The extent of microbial eradication was dependent on the MIC for the S. pneumoniae isolate. Substantial bactericidal activities (i.e., killing of approximately 2 log CFU per thigh) were consistently observed against isolates for which MICs were Assuntos
Antibacterianos/uso terapêutico
, Lactamas
, Doenças Musculares/tratamento farmacológico
, Neutropenia/tratamento farmacológico
, Streptococcus pneumoniae/efeitos dos fármacos
, Animais
, Antibacterianos/farmacocinética
, Ertapenem
, Feminino
, Camundongos
, Camundongos Endogâmicos ICR
, Doenças Musculares/microbiologia
, Doenças Musculares/mortalidade
, Neutropenia/microbiologia
, Neutropenia/mortalidade
, Ligação Proteica
, Análise de Sobrevida
, beta-Lactamas
RESUMO
Febrile neutropenia is a common and potentially fatal problem encountered in cancer patients undergoing chemotherapy. We carried out an observational study to evaluate the possible risk factors of developing fever amongst neutropenic children with an underlying malignancy. We also looked at the microbiological profile of causative pathogens in patients with febrile neutropenia. During a study period of 1 year, a total of 90 neutropenic episodes were recorded amongst 57 patients who were on treatment and follow-up during the study period. Multivariate analysis showed that factors such as chemotherapy status, underlying disease, existing central venous catheters, presenting white blood cell counts at chemotherapy, use of steroid therapy or hospitalisation at the onset of neutropenia, were not significant risk factors for developing fever during neutropenic episodes. Although the presence of a central venous catheter was associated with a higher risk of developing fever, it did not reach statistical significance (p=0.11). Of the 90 neutropenic episodes, 59 (65.6%) developed fever and 25 of these had positive blood cultures. The causative organisms include gram-negative bacteria (64%), gram positive bacteria (16%) and fungus (20%). Of the gram-negative organisms, Klebsiella spp. predominated (28%) with the extended spectrum beta-lactamase producing strain forming the majority (16%). Amongst those with fungaemia, Candida spp. and Candida tropicalis formed the majority (8% each) of the isolates.
Assuntos
Infecção Hospitalar/epidemiologia , Febre/etiologia , Neoplasias/complicações , Neutropenia/epidemiologia , Adolescente , Antineoplásicos/efeitos adversos , Criança , Pré-Escolar , Infecção Hospitalar/complicações , Infecção Hospitalar/microbiologia , Feminino , Febre/microbiologia , Humanos , Lactente , Malásia/epidemiologia , Masculino , Neoplasias/tratamento farmacológico , Neoplasias/microbiologia , Neutropenia/etiologia , Neutropenia/microbiologia , Fatores de RiscoRESUMO
Quinolones are increasingly used as prophylaxis in neutropenic patients to prevent serious Gram-negative septicaemias but practice is not uniform because of the controversial evidence as to their effectiveness. It is unclear if they are of real benefit in patients with short episodes of neutropenia such as those resulting from treatment for solid tumours and lymphomas. The concern over the use of ciprofloxacin in such settings is the increasing development of quinolone resistant Gram-negative bacteria. We have retrospectively analysed our bacterial isolate resistance patterns in the Queen Elizabeth Hospital (QE) and in the Haematology Department of the Aga Khan Hospital (AKU), Pakistan where all patients would receive ciprofloxacin prophylaxis when neutropenic. Seven out of 57 (12.2%) and 18 out of 55 (32.7%) Gram-negative organisms isolated from blood cultures at the QE and AKU Haematology Departments, respectively, were resistant to ciprofloxacin (P < 0.01). In the Birmingham community this was significantly lower (P < 0.01) (55 out of 6423: 0.85%). We also showed a higher level of E. coli resistance at the AKU (18 out of 31: 58%) where ciprofloxacin use was more widespread than at the QE (1 out of 11, P < 0.01). We conclude that ciprofloxacin should not be used indiscriminately.
Assuntos
Anti-Infecciosos/uso terapêutico , Bacteriemia/epidemiologia , Resistência Microbiana a Medicamentos , Neutropenia/tratamento farmacológico , Bacteriemia/tratamento farmacológico , Bacteriemia/prevenção & controle , Ciprofloxacina/uso terapêutico , Prescrições de Medicamentos , Controle de Medicamentos e Entorpecentes , Bactérias Gram-Negativas/classificação , Bactérias Gram-Negativas/isolamento & purificação , Humanos , Incidência , Neutropenia/complicações , Neutropenia/microbiologia , Paquistão , Estudos Retrospectivos , Reino UnidoRESUMO
Infection remains an important cause of morbidity and mortality after bone marrow or stem cell transplantation. To evaluate the role of obtaining blood cultures for intermittent or persistent fever in neutropenic patients on antibiotic therapy, we performed a retrospective chart review of 196 consecutive patients admitted to the Bone Marrow Transplant Unit at the University of North Carolina Hospitals from 1995 to 1998. From the cohort of 196 patients, 154 patients developed neutropenic fever. The initial blood culture was positive in 16 of 145 patients during the first fever episode giving a prevalence of 11%. From the total of 109 patients that had blood cultures drawn after day 1 of fever, five patients had blood cultures positive for a pathogen, a prevalence of 4.6%. In only one patient, did blood cultures drawn after day 1 identify an organism not present on day 1 (prevalence 0.9%). After reviewing the results in the first 105 patients, we changed our timing of collection of blood cultures. Forty-nine patients were treated in this manner and we found that the mean number of blood cultures decreased from 9.2 to 4.7 per patient without a change in the frequency of infectious complications or length of hospitalization.